维康药业
(300878)
| 流通市值：25.26亿 | | | 总市值：25.38亿 |
| 流通股本：1.44亿 | | | 总股本：1.45亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 370,849,453.15 | 296,988,424.32 | 199,953,044.93 | 519,621,071.15 |
| 营业收入 | 370,849,453.15 | 296,988,424.32 | 199,953,044.93 | 519,621,071.15 |
| 二、营业总成本 | 414,716,527.66 | 285,139,187.4 | 173,888,443.65 | 560,065,209.92 |
| 营业成本 | 195,105,928.34 | 143,888,073.03 | 102,127,742.39 | 257,763,389.96 |
| 税金及附加 | 9,052,229.65 | 5,579,944.16 | 4,721,783.8 | 2,813,582.74 |
| 销售费用 | 163,238,779.57 | 105,652,239.67 | 52,336,889.43 | 208,186,400.97 |
| 管理费用 | 33,169,543.96 | 21,783,663.26 | 10,773,840.43 | 40,941,584.86 |
| 研发费用 | 12,180,680.93 | 6,580,329.95 | 2,971,220.93 | 42,798,186.43 |
| 财务费用 | 1,969,365.21 | 1,654,937.33 | 956,966.67 | 7,562,064.96 |
| 其中:利息费用 | 4,200,156.35 | 3,182,768.87 | 1,242,219.45 | 9,449,684.78 |
| 其中:利息收入 | 2,314,974.21 | 1,576,931.51 | 616,539.48 | 1,978,923.07 |
| 加:公允价值变动收益 | - | - | 2,192,798.4 | 4,564,629.39 |
| 加:投资收益 | 92,107,925.62 | 2,144,813.87 | 1,245,053.9 | 13,867,915.07 |
| 资产处置收益 | -251,107.37 | -271,315.57 | -30,532.26 | -5,821.95 |
| 资产减值损失(新) | -123,728.8 | -92,187.59 | -34,612.01 | -736,974.52 |
| 信用减值损失(新) | -6,588,421.43 | -3,945,320.32 | -4,978,010.08 | 11,461,123.46 |
| 其他收益 | 6,783,853.17 | 3,882,660.41 | 2,174,772.84 | 10,279,773.63 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 48,061,446.68 | 13,567,887.72 | 26,634,072.07 | -1,013,493.69 |
| 加:营业外收入 | 3,082,327.88 | 2,799,410.1 | 35,801.23 | 518,785.49 |
| 减:营业外支出 | 7,315,564.82 | 269,463.55 | 318,760.97 | 5,291,187.6 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 43,828,209.74 | 16,097,834.27 | 26,351,112.33 | -5,785,895.8 |
| 减:所得税费用 | -2,376,861.32 | 117,507.39 | 1,961,788.37 | 398,592.69 |
| 六、净利润 | 46,205,071.06 | 15,980,326.88 | 24,389,323.96 | -6,184,488.49 |
| 持续经营净利润 | 46,205,071.06 | 15,980,326.88 | 24,389,323.96 | -6,184,488.49 |
| 归属于母公司股东的净利润 | 44,097,475.42 | 14,192,094.75 | 24,334,978.24 | -8,038,557.83 |
| 少数股东损益 | 2,107,595.64 | 1,788,232.13 | 54,345.72 | 1,854,069.34 |
| (一)基本每股收益 | 0.31 | 0.1 | 0.17 | -0.06 |
| (二)稀释每股收益 | 0.31 | 0.1 | 0.17 | -0.06 |
| 九、综合收益总额 | 46,205,071.06 | 15,980,326.88 | 24,389,323.96 | -6,184,488.49 |
| 归属于母公司股东的综合收益总额 | 44,097,475.42 | 14,192,094.75 | 24,334,978.24 | -8,038,557.83 |
| 归属于少数股东的综合收益总额 | 2,107,595.64 | 1,788,232.13 | 54,345.72 | 1,854,069.34 |
| 公告日期 | 2024-10-28 | 2024-08-30 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 保留意见 |